Bosentan

證據等級: L5

預測適應症: 9 個

Bosentan: From Pulmonary Arterial Hypertension to Rheumatoid Arthritis

One-Sentence Summary

Bosentan is a dual endothelin receptor antagonist (ERA) originally developed for pulmonary arterial hypertension (PAH), where it reduces pulmonary vascular resistance by blocking both ETA and ETB receptors. The TxGNN model predicts it may be effective for Rheumatoid Arthritis (RA), supported by 1 clinical trial (indirect, for Giant Cell Arteritis) and 16 publications — primarily preclinical animal studies and reviews. Current evidence is mechanistically plausible but lacks direct human RCT support; this remains a research hypothesis requiring prospective validation.

Quick Overview

Item	Content
Original Indication	Pulmonary Arterial Hypertension (global approval; no New Zealand authorization on record)
Predicted New Indication	Rheumatoid Arthritis
TxGNN Prediction Score	99.80%
Evidence Level	L3 (Preclinical + Observational)
New Zealand Market Status	Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available from the Evidence Pack. Based on known pharmacology, Bosentan is a dual ETA/ETB receptor antagonist that blocks the actions of endothelin-1 (ET-1), a potent vasoconstrictor and pro-fibrotic peptide. Its established efficacy in PAH is built on reducing pulmonary vascular remodelling driven by excessive ET-1 signalling.

The mechanistic link to RA is biologically plausible: ET-1 is significantly elevated in the synovial fluid of RA patients, where it activates NF-κB signalling to drive the release of pro-inflammatory cytokines (TNF-α, IL-1β) and sustains synovial hyperplasia. By blocking both ETA and ETB receptors, Bosentan could theoretically interrupt this inflammatory amplification loop within the joint microenvironment.

Animal models provide initial support for this hypothesis. In collagen-induced arthritis (CIA) and zymosan-induced arthritis mouse models, dual ET receptor blockade reduced joint inflammation, neutrophil accumulation, and oedema formation. However, no human clinical trial has directly tested Bosentan in RA patients. The sole registered trial (NCT06957002) targets Giant Cell Arteritis — a related but distinct autoimmune vasculitis — offering indirect mechanistic support rather than direct RA evidence.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT06957002	Phase 2	Not Yet Recruiting	40	Bosentan + glucocorticoids vs. glucocorticoids alone in Giant Cell Arteritis (GCA); primary endpoint is failure-free survival at 12 months. GCA shares ET-1 overactivation with RA but is a distinct vasculitis entity — provides indirect mechanistic support only. Results not yet available.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
22249931	2012	Animal Study	Inflammation Research	Bosentan (dual ETA/ETB antagonist) ameliorates collagen-induced arthritis in mice; TNF-α shown to upregulate endothelin system genes, establishing the ET-1/TNF-α axis in RA pathology
18515326	2008	Animal Study	Journal of Leukocyte Biology	ET-1 levels elevated in plasma and synovial membrane of RA patients; selective ETA/ETB blockade reduces neutrophil accumulation and oedema in zymosan-induced arthritis model
16766656	2006	Animal Study	PNAS	IL-15-induced mechanical hypernociception in RA inhibited by dual endothelin receptor blockade; identifies ET pathway as downstream mediator of RA-associated pain
19969421	2010	Animal Study	Pain	IL-17 drives articular hypernociception in antigen-induced arthritis; contextualises the cytokine–ET-1 inflammatory network relevant to ET receptor antagonism
20054770	2009	Case Report	Kardiologia Polska	8.5-year-old with Eisenmenger syndrome treated with Bosentan concurrently diagnosed with juvenile rheumatoid arthritis; clinical improvement on Bosentan noted, though PAH was the primary indication
24268012	2014	Review	Rheumatic Diseases Clinics of North America	PAH associated with CTDs including RA reviewed; ET-1-targeted therapies (including Bosentan) discussed in the context of connective tissue disease complications
19487226	2009	Review	Rheumatology (Oxford)	Vascular disease in SLE, Sjögren's syndrome, and necrotizing vasculitides; ET-1 signalling central to CTD-associated PAH — mechanistic context for ERA use in rheumatic disease
16218473	2005	Review	Lupus	PAH in CTDs including RA, dermatomyositis, Sjögren's; establishes prevalence of ET-1-driven vascular complications across rheumatic diseases
19851110	2010	Review	Current Opinion in Rheumatology	Reviews pathophysiology and therapies of rheumatic skin diseases; skin used as primary endpoint for evaluating therapies — contextual background for ET-1 involvement
18238768	2008	Review	AJHP	Current and emerging drug therapy for systemic sclerosis complications; Bosentan discussed as an ET receptor antagonist with potential disease-modifying applications across CTDs

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: While the ET-1/ETA/ETB mechanistic link to RA is biologically coherent and supported by two independent animal arthritis models, there is no direct human clinical trial evidence for Bosentan in RA. The single registered trial targets a related but different condition (GCA), and all literature consists of preclinical studies, reviews, and a single tangentially relevant case report — placing this at evidence level L3 with no clinical efficacy data to draw from.

To proceed, the following is needed:

Retrieve Bosentan's full mechanism of action data (DrugBank API) and package insert warnings/contraindications (TFDA/Medsafe PDF) to complete the safety assessment
Conduct a pilot open-label clinical study or at minimum a retrospective cohort analysis in RA patients who have received Bosentan for comorbid PAH or digital ulcers, to collect human efficacy signals
Establish a clear disease differentiation rationale: given Bosentan already has strong evidence in limited systemic sclerosis (L1, RAPIDS-1 and RAPIDS-2 Phase 3 RCTs), prioritising SSc-related RA overlap patients may offer a more feasible clinical pathway
Clarify drug interaction profile — Bosentan is a known CYP3A4/CYP2C9 inducer with significant interaction potential (warfarin, cyclosporin, glibenclamide), which is especially relevant if combined with standard RA biologics or DMARDs
Define target patient subpopulation: RA patients with elevated synovial ET-1, concurrent Raynaud's phenomenon, or CTD overlap may be the most suitable candidates for a proof-of-concept study
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.